New stock news | First for Da Sheng Biotechnology's IPO prospectus to be invalid

Hangzhou Xianweida Biotechnology Co., Ltd.-B (hereinafter referred to as Xianweida Biotechnology) submitted its Hong Kong IPO prospectus on September 19, 2025 for a period of 6 months, which will expire on March 19, 2026. Morgan Stanley and CICC were the joint sponsors at the time of submission. According to the prospectus, Xianweida Biotechnology is a biopharmaceutical company approaching the commercialization stage, dedicated to meeting the urgent medical needs in the field of weight management. The company is about to launch Exenatide Injection (XW003, the company's core product) in China, which is expected to become the world's first cAMP-biased GLP-1 receptor agonist for the treatment of overweight/obesity and type 2 diabetes. Based on the clinical data published by Xianweida Biotechnology, Exenatide Injection (XW003) achieved a placebo-adjusted weight loss effect of 15.1% in Chinese overweight/obese patients (with an average weight loss of 17.6% in females), surpassing Semaglutide (8.5%), and achieving the efficacy of liraglutide at a lower dosage (2.4mg vs 15mg).